Skye Bioscience Inc
NASDAQ:SKYE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.727
4.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Skye Bioscience Inc
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.
Cash Position: Skye ended Q3 with $35.3 million in cash and investments, expected to fund operations and milestones into 2027.
Clinical Data: Phase IIa study of nimasimab plus semaglutide showed about a 3% additional weight loss at 26 weeks compared to semaglutide alone, representing nearly a 30% improvement with no observed plateau.
Durability & Safety: The combination blunted weight regain after treatment, with only 18% regain versus 50% for semaglutide alone; no neuropsychiatric or additive GI side effects observed.
R&D Spending: R&D expenses rose to $9.4 million from $4.9 million year-over-year, due to manufacturing, trial costs, and increased compensation.
Net Loss: Net loss for the quarter was $12.8 million.
Forward Outlook: Extension study data expected in late Q1 or early Q2 2026; company plans to continue dose escalation and initiate new combination studies.
Manufacturing Progress: High concentration formulation and manufacturing scale-up remain on track to support larger clinical trials and future commercialization.
